this is called "spin" taylor. I understand they have a minimum amount to purchase. The point is they are paying Hikma much more than they were going to pay to have their own ANDA manufactured. So he payed the ANDA filing fees to the FDA(which is now MIA) and now he's paying Hikma more for Fluti than planned for. That throws Honeycomb's 70-80% gross margins right out the window. That's called a lose-lose, not a win-win, especially with a forced hand at the end of allergy season. You don't negotiate deals in your career, do you?
Market Data 
Markets 
AI
